Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Capital Markets

Johnson & Johnson / Equity Capital Markets

<ul><li>Johnson & Johnson had a dream Q2 result with global sales touching $23.3 billion, a growth of a staggering 27.1% as compared to the second quarter of 2020.</li><li>The company has been performing well across all core segments and the big surprise for investors was the recovery in the Baby Care franchise which increased by 5% due to market recovery and OUS strength.</li><li>The company has a strong upside from robotic surgical systems as well as increased penetration of its easy-to-store, single-dose vaccine in markets like India.</li></ul>

Johnson & Johnson had a dream Q2 result with global sales touching $23.3 billion, a growth of a staggering 27.1% as compared to the second quarter of 2020.The company has been performing well across all core segments and the big surprise for investors was the recovery in the Baby Care franchise which increased by 5% due to market recovery and OUS strength.The company has a strong upside from robotic surgical systems as well as increased penetration of its easy-to-store, single-dose vaccine in markets like India.

Quality-first, Business-perspective Strategy, Urbem (HK) Limited

Steven Chen

Quality-first, Business-perspective Strategy

Equity Bottom-Up

<ul>
<li>I seldom touched those unpredicatble biotech stocks, but Bioventix is an exception;</li>
<li>The company provides a bond-like cash streams for its owners, through a well-moated, highly predictable business model;</li>
<li>Although it is not clear whether the share can offer a 20% total return at this price level, I see a high chance for it to outperform the market benchmark with a limited downside from here in the long run.</li>
</ul>


I seldom touched those unpredicatble biotech stocks, but Bioventix is an exception;
The company provides a bond-like cash streams for its owners, through a well-moated, highly predictable business model;
Although it is not clear whether the share can offer a 20% total return at this price level, I see a high chance for it to outperform the market benchmark with a limited downside from here in the long run.


Bioventix: A Rare Biotech Play with a Low-Risk, High-Return Model

Bond market data and technology, BondEvalue

BondEvalue

Bond market data and technology

BondEvalue is a Singapore-based Fintech that specializes in bond market data and technology. The company's information services business offers bond market data on hard-currency corporate & sovereign bonds across Asia, Middle East, Europe and the Americas. The data, which includes bond prices, yields, news and analytics, is offered to end investors via interactive Mobile and Web Apps. Investors can sign up for a free trial of the service either via the company's website (https://bondevalue.com) or by downloading the BondEvalue Mobile App (http://onelink.to/wej7jq). BondEvalue is also developing an electronic bond exchange, BondbloX in Singapore that allows investors to trade bonds electronically in smaller sizes (US$1,000 or equivalent). For more information, visit https://www.bondblox.com/

Bond Market Data and Technology

Credit

US markets extended the rebound rally for a second day amid strong corporate earnings –  S&amp;P and Nasdaq gained 0.8% and 0.9% respectively. Energy zoomed 3.9% with Brent Crude going back above $70/bbl, Financials and Industrials were up more than 1%. Corporate earnings continued with Coca Cola, J&amp;J, Verizon and Julius Baer reporting strong numbers (scroll down for details). US 10Y Treasury yields rose 8bp to 1.29%. European bourses also extended their gains – CAC, FTSE and DAX were up 1.9%, 1.7% and 1.4% respectively. US IG CDS spreads tightened 1bp and HY tightened 8bp. EU Main and Crossover spreads tightened 1.6bp and 8.1bp respectively. Brazil’s Bovespa was up 0.4%. Gulf markets remained closed for Eid. Asian markets continued the strong momentum and opened higher – HSI was up 1.9%, Nikkei and Singapore’s STI were up 0.6% and Shanghai was up 0.2%. Asia ex-Japan CDS spreads were 0.4bp tighter.

CK Infra, Ping An Launch $ Bonds; Macro; Rating Changes; New Issues; Talking Heads; Top Gainers &...

Asian Insight Provider - Actionable ideas, CrossASEAN Research

Henry Soediarko

Asian Insight Provider - Actionable ideas

CrossASEAN Research

At CrossASEAN Research we strive to produce unbiased and differentiated on the ground insights on companies across South East Asia. Our Research is produced for the most part after face to face meetings and conversations with company management to dig deep into the long term vision and strategy of the companies we cover. We seek to deliver investable and actionable themes on sectors and markets across SE Asia, often in collaboration with other Insight Providers across the region, pooling the vast experience of the analysts within the Smartkarma Ecosystem. We also offer bespoke work and tailor made trips for our clients. 

Insights across South East Asia

Due to the worsening COVID-19 conditions in Thailand, investors may sell off Airport of Thailand's share in the coming months although the long-term prospect remains solid; global inoculation is on the way and governments around the world keep tinkering with the travel bubble that helps to provide more ideas on how to restart travel, mainly in safe entry and quarantine protocols. 
<div class="content-highlight">
Therefore, investors should take advantage of the potential sell-off in <a href="https://www.smartkarma.com/entities/airports-of-thailand-pcl" target="_blank" data-smartkarma-citation="entities:239:1" rel="noopener">Airports of Thailand (AOT TB)</a> to add and should benefit later when travel recovers. Third Wave is a Charm.
</div>

Due to the worsening COVID-19 conditions in Thailand, investors may sell off Airport of Thailand's share in the coming months although the long-term prospect remains solid; global inoculation is on the way and governments around the world keep tinkering with the travel bubble that helps to provide more ideas on how to restart travel, mainly in safe entry and quarantine protocols. 

Therefore, investors should take advantage of the potential sell-off in Airports of Thailand (AOT TB) to add and should benefit later when travel recovers. Third Wave is a Charm.


Airport of Thailand (AOT): 3rd Wave Is a Charm

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Livzon Pharmaceutical Group In / Equity Bottom-Up

<a href="https://www.smartkarma.com/entities/livzon-pharmaceutical-group-a" target="_blank" data-smartkarma-citation="entities:24770:1" rel="noopener">Livzon Pharmaceutical Group-A (000513 CH)</a> released its third quarter report in 2020. The Q1-Q3 accumulated revenue was RMB7.926 billion, with a YoY growth rate of 8.64%. Net income attributed to shareholders in the first three quarters was RMB1.422 billion, up 36.71% YoY. Net income after deducting non-recurring gains and losses were RMB1.179 billion, up 23.15% YoY. Q3 single quarter revenue was RMB2.83 billion, up 20.14% YoY. Net income attributed to shareholders reached RMB417 million, up 38.52% YoY. Q3’s single quarter net income after deducting non-recurring gains and losses was RMB344 million, up 15.28% YoY. Q3 performance was above expectations, with the highest YoY growth rate in the single quarter in nearly three years, and demonstrated strong recovery in various sectors.<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/175/696/original/image_32979984121606785555504.png?1606785557" class="editor-image img-responsive" data-smartkarma-image-id="175696"></figure>Source: WIND

Livzon Pharmaceutical Group-A (000513 CH) released its third quarter report in 2020. The Q1-Q3 accumulated revenue was RMB7.926 billion, with a YoY growth rate of 8.64%. Net income attributed to shareholders in the first three quarters was RMB1.422 billion, up 36.71% YoY. Net income after deducting non-recurring gains and losses were RMB1.179 billion, up 23.15% YoY. Q3 single quarter revenue was RMB2.83 billion, up 20.14% YoY. Net income attributed to shareholders reached RMB417 million, up 38.52% YoY. Q3’s single quarter net income after deducting non-recurring gains and losses was RMB344 million, up 15.28% YoY. Q3 performance was above expectations, with the highest YoY growth rate in the single quarter in nearly three years, and demonstrated strong recovery in various sectors.Source: WIND

Livzon Pharmaceutical (000513.CH) - A Good Company that You Can't Afford Missing

United States

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets.  The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Johnson & Johnson (JNJ US)

Johnson & Johnson - Investment Thesis

Johnson & Johnson had a dream Q2 result with global sales touching $23.3 billion, a growth of a staggering 27.1% as compared to the second...

Baptista Research

Bioventix: A Rare Biotech Play with a Low-Risk, High-Return Model

Although it is not clear whether this bond proxy can offer a 20% total return at this level, I see a high chance for it to outperform the benchmark...

Steven Chen

CK Infra, Ping An Launch $ Bonds; Macro; Rating Changes; New Issues; Talking Heads; Top Gainers &...

US markets extended the rebound rally for a second day amid strong corporate earnings – S&P and Nasdaq gained 0.8% and 0.9% respectively....

BondEvalue

Airport of Thailand (AOT): 3rd Wave Is a Charm

The sell off AOT soon due to worsening conditions in the third wave of the COVID-19 outbreak.Investors should take advantage of the sell-off in...

Henry Soediarko

Livzon Pharmaceutical (000513.CH) - A Good Company that You Can't Afford Missing

This article analyzed Livzon's R&D highlights, main products and pipelines, financial position, and made forecast and rating for the Company.

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)